Insider Transactions Reported by 21 Insiders of Quince Therapeutics, Inc.

Symbol
QNCX on Nasdaq
Location
South San Francisco, CA

Insiders trading volume in the past year

Quince Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Dirk Thye CEO and CMO, Director $1,690,274 23 Jan 2026
Philip S. Low Director $488,126 19 May 2022
Brendan Hannah Cbo, Coo & Cco $344,834 23 Jan 2026
Christopher P. Lowe Interim CEO, COO & CFO $249,100 03 Mar 2022
Charles S. Ryan President $156,953 23 Jan 2026
Leslie Holsinger EVP, Preclinical Development $139,195 06 Jun 2022
Luca Benatti Director $135,951 -$173,500 -56% 26 Dec 2025
Michael J. Detke Chief Medical Officer $131,600 03 Mar 2022
Caryn Gordon McDowell Chief Legal & Adm. Officer $115,150 06 Jun 2022
Ted Monohon Chief Accounting Officer & VP $25,794 06 Mar 2023
Guenter Janhofer Chief Scientific Officer $14,108 23 Oct 2023
Marwan Sabbagh Director 14 Mar 2022
Casey Lynch Chief Executive Officer, Director 03 Jan 2022
Stephen S. Dominy Chief Scientific Officer, Director 03 Jan 2022
Karen L. Smith Chief Medical Officer 01 Feb 2023
Rajiv Patni Director 04 Jun 2025
Una S. Ryan Director 04 Jun 2025
Christopher J. Senner Director 02 Jan 2026
David Lamond Director 02 Jan 2026
Margaret McLoughlin Director 02 Jan 2026
June Bray Director 02 Jan 2026

Recent Insider Transactions by Companies or Individuals for Quince Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Brendan Hannah QNCX Employee Stock Option (Right to Buy) Award -50% -365,000 365,000 23 Jan 2026 Direct
Dirk Thye QNCX Employee Stock Option (Right to Buy) Award 1,000,000 1,000,000 23 Jan 2026 Direct
Charles S. Ryan QNCX Employee Stock Option (Right to Buy) Award 200,000 200,000 23 Jan 2026 Direct
Christopher J. Senner QNCX Director Stock Option (Right to Buy) Award 21,810 21,810 02 Jan 2026 Direct
Margaret McLoughlin QNCX Director Stock Option (Right to Buy) Award 19,547 19,547 02 Jan 2026 Direct
David Lamond QNCX Director Stock Option (Right to Buy) Award 29,423 29,423 02 Jan 2026 Direct
June Bray QNCX Director Stock Option (Right to Buy) Award 18,724 18,724 02 Jan 2026 Direct
Luca Benatti QNCX Common Stock Sale -56.1% $173,500 $3.47 -50,000 39,179 26 Dec 2025 Direct
Dirk Thye QNCX Common Shares Gift 739,885 739,885 10 Dec 2025 Thye Trust
Dirk Thye QNCX Common Shares Gift -74.4% -739,885 255,000 10 Dec 2025 Direct
Brendan Hannah QNCX Common Shares Options Exercise 8.24% 27,551 361,827 05 Dec 2025 Direct
Brendan Hannah QNCX Employee Stock Option (Right to Buy) Options Exercise -37.9% -27,551 45,168 05 Dec 2025 Direct
Brendan Hannah QNCX Common Shares Award 12.7% 37,736 334,276 18 Jun 2025 Direct
Brendan Hannah QNCX Warrants Award 37,736 37,736 18 Jun 2025 Direct
Charles S. Ryan QNCX Common Shares Award 6.16% 7,548 130,009 18 Jun 2025 Direct
Charles S. Ryan QNCX Warrants Award 7,548 7,548 18 Jun 2025 Direct
Dirk Thye QNCX Common Shares Award 17.9% 150,944 994,885 18 Jun 2025 Direct
Dirk Thye QNCX Warrants Award 150,944 150,944 18 Jun 2025 Direct
Una S. Ryan QNCX Director Stock Option (Right to Buy) Award 27,000 27,000 04 Jun 2025 Direct
Luca Benatti QNCX Director Stock Option (Right to Buy) Award 27,000 27,000 04 Jun 2025 Direct
Christopher J. Senner QNCX Director Stock Option (Right to Buy) Award 27,000 27,000 04 Jun 2025 Direct
David Lamond QNCX Director Stock Option (Right to Buy) Award 27,000 27,000 04 Jun 2025 Direct
Margaret McLoughlin QNCX Director Stock Option (Right to Buy) Award 27,000 27,000 04 Jun 2025 Direct
Rajiv Patni QNCX Director Stock Option (Right to Buy) Award 27,000 27,000 04 Jun 2025 Direct
June Bray QNCX Director Stock Option (Right to Buy) Award 27,000 27,000 04 Jun 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.